Beta Bionics, Inc. is a commercial-stage medical device company. The Company offers an automated insulin delivery system with closed-loop algorithms for the treatment of people with diabetes. Beta Bionics operates in the United States.

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Current Report (Form 8-K | Period ending 2025-01-31)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Beta Bionics (BBNX US)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Current Report (Form 8-K | Period ending 2025-01-31)

424B4 | Prospectus

S-1MEF | A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S 1

S-1/A | IPO Registration (Amendment)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)